Literature DB >> 25425688

A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.

Sarit Assouline1, Biljana Culjkovic-Kraljacic2, Julie Bergeron3, Stephen Caplan4, Eftihia Cocolakis4, Caroline Lambert4, Cara J Lau4, Hiba Ahmad Zahreddine2, Wilson H Miller4, Katherine L B Borden5.   

Abstract

Entities:  

Keywords:  AML; drug resistance; eIF4E; phase I; ribavirin

Mesh：

Substances：

Year:  2014        PMID： 25425688      PMCID： PMC4281321          DOI： 10.3324/haematol.2014.111245

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

Review 1.  Further evidence that ribavirin interacts with eIF4E.

Authors:  Alex Kentsis; Laurent Volpon; Ivan Topisirovic; Clifford E Soll; Biljana Culjkovic; Ling Shao; Katherine L B Borden
Journal:  RNA       Date:  2005-10-26       Impact factor: 4.942

2.  Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens.

Authors:  B C Kraljacic; M Arguello; A Amri; G Cormack; K Borden
Journal:  Leukemia       Date:  2011-04-01       Impact factor: 11.528

3.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors:  David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

4.  Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap.

Authors:  Alex Kentsis; Ivan Topisirovic; Biljana Culjkovic; Ling Shao; Katherine L B Borden
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-15       Impact factor: 11.205

Review 5.  The oncogene eIF4E: using biochemical insights to target cancer.

Authors:  Martin Carroll; Katherine L B Borden
Journal:  J Interferon Cytokine Res       Date:  2013-03-08       Impact factor: 2.607

6.  Inhibition of digoxin absorption but not of digitoxin during cytostatic drug therapy.

Authors:  J Kuhlmann
Journal:  Arzneimittelforschung       Date:  1982

7.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Authors:  Timothy J Ley; Christopher Miller; Li Ding; Benjamin J Raphael; Andrew J Mungall; A Gordon Robertson; Katherine Hoadley; Timothy J Triche; Peter W Laird; Jack D Baty; Lucinda L Fulton; Robert Fulton; Sharon E Heath; Joelle Kalicki-Veizer; Cyriac Kandoth; Jeffery M Klco; Daniel C Koboldt; Krishna-Latha Kanchi; Shashikant Kulkarni; Tamara L Lamprecht; David E Larson; Ling Lin; Charles Lu; Michael D McLellan; Joshua F McMichael; Jacqueline Payton; Heather Schmidt; David H Spencer; Michael H Tomasson; John W Wallis; Lukas D Wartman; Mark A Watson; John Welch; Michael C Wendl; Adrian Ally; Miruna Balasundaram; Inanc Birol; Yaron Butterfield; Readman Chiu; Andy Chu; Eric Chuah; Hye-Jung Chun; Richard Corbett; Noreen Dhalla; Ranabir Guin; An He; Carrie Hirst; Martin Hirst; Robert A Holt; Steven Jones; Aly Karsan; Darlene Lee; Haiyan I Li; Marco A Marra; Michael Mayo; Richard A Moore; Karen Mungall; Jeremy Parker; Erin Pleasance; Patrick Plettner; Jacquie Schein; Dominik Stoll; Lucas Swanson; Angela Tam; Nina Thiessen; Richard Varhol; Natasja Wye; Yongjun Zhao; Stacey Gabriel; Gad Getz; Carrie Sougnez; Lihua Zou; Mark D M Leiserson; Fabio Vandin; Hsin-Ta Wu; Frederick Applebaum; Stephen B Baylin; Rehan Akbani; Bradley M Broom; Ken Chen; Thomas C Motter; Khanh Nguyen; John N Weinstein; Nianziang Zhang; Martin L Ferguson; Christopher Adams; Aaron Black; Jay Bowen; Julie Gastier-Foster; Thomas Grossman; Tara Lichtenberg; Lisa Wise; Tanja Davidsen; John A Demchok; Kenna R Mills Shaw; Margi Sheth; Heidi J Sofia; Liming Yang; James R Downing; Greg Eley
Journal:  N Engl J Med       Date:  2013-05-01       Impact factor: 91.245

8.  eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3'UTR.

Authors:  Biljana Culjkovic; Ivan Topisirovic; Lucy Skrabanek; Melisa Ruiz-Gutierrez; Katherine L B Borden
Journal:  J Cell Biol       Date:  2005-04-18       Impact factor: 10.539

9.  The eIF4E RNA regulon promotes the Akt signaling pathway.

Authors:  Biljana Culjkovic; Keith Tan; Slobodanka Orolicki; Abdellatif Amri; Sylvain Meloche; Katherine L B Borden
Journal:  J Cell Biol       Date:  2008-04-07       Impact factor: 10.539

10.  The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.

Authors:  Hiba Ahmad Zahreddine; Biljana Culjkovic-Kraljacic; Sarit Assouline; Patrick Gendron; Andrea A Romeo; Stephen J Morris; Gregory Cormack; James B Jaquith; Leandro Cerchietti; Eftihia Cocolakis; Abdellatif Amri; Julie Bergeron; Brian Leber; Michael W Becker; Shanshan Pei; Craig T Jordan; Wilson H Miller; Katherine L B Borden
Journal:  Nature       Date:  2014-05-28       Impact factor: 49.962
View more
  28 in total

1.  Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.

Authors:  Biljana Culjkovic-Kraljacic; Tharu M Fernando; Rossella Marullo; Nieves Calvo-Vidal; Akanksha Verma; ShaoNing Yang; Fabrizio Tabbò; Marcello Gaudiano; Hiba Zahreddine; Rebecca L Goldstein; Jayeshkumar Patel; Tony Taldone; Gabriela Chiosis; Marco Ladetto; Paola Ghione; Rodolfo Machiorlatti; Olivier Elemento; Giorgio Inghirami; Ari Melnick; Katherine L B Borden; Leandro Cerchietti
Journal:  Blood       Date:  2015-11-24       Impact factor: 22.113

2.  Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.

Authors:  Rossella Marullo; Sarah C Rutherford; John P Leonard; Leandro Cerchietti
Journal:  Cell Cycle       Date:  2016-07-15       Impact factor: 4.534

3.  Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes.

Authors:  Michael J Osborne; Luciana Coutinho de Oliveira; Laurent Volpon; Hiba Ahmad Zahreddine; Katherine L B Borden
Journal:  J Mol Biol       Date:  2018-11-11       Impact factor: 5.469

4.  Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells.

Authors:  Hiba Ahmad Zahreddine; Katherine L B Borden
Journal:  Clin Cancer Res       Date:  2015-03-25       Impact factor: 12.531

Review 5.  When will resistance be futile?

Authors:  Katherine L B Borden
Journal:  Cancer Res       Date:  2014-12-04       Impact factor: 12.701

6.  Targeted Dual pH-Sensitive Lipid ECO/siRNA Self-Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy.

Authors:  Maneesh Gujrati; Amita M Vaidya; Margaret Mack; Dayton Snyder; Anthony Malamas; Zheng-Rong Lu
Journal:  Adv Healthc Mater       Date:  2016-10-10       Impact factor: 9.933

7.  Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.

Authors:  F Volpin; J Casaos; J Sesen; A Mangraviti; J Choi; N Gorelick; J Frikeche; T Lott; R Felder; S J Scotland; T S K Eisinger-Mathason; H Brem; B Tyler; N Skuli
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

8.  Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E.

Authors:  Laurent Volpon; Biljana Culjkovic-Kraljacic; Michael J Osborne; Anup Ramteke; Qingxiang Sun; Ashley Niesman; Yuh Min Chook; Katherine L B Borden
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-25       Impact factor: 11.205

9.  Structural studies of the eIF4E-VPg complex reveal a direct competition for capped RNA: Implications for translation.

Authors:  Luciana Coutinho de Oliveira; Laurent Volpon; Amanda K Rahardjo; Michael J Osborne; Biljana Culjkovic-Kraljacic; Christian Trahan; Marlene Oeffinger; Benjamin H Kwok; Katherine L B Borden
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-11       Impact factor: 11.205

10.  Backbone assignment of the apo-form of the human C-terminal domain of UDP-glucuronosyltransferase 1A (UGT1A).

Authors:  Michael J Osborne; Luciana Coutinho de Oliveira; Laurent Volpon; Katherine L B Borden
Journal:  Biomol NMR Assign       Date:  2018-06-22       Impact factor: 0.746
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.